The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Veness Adam M since 2019.
This trader's CIK number is 1778623.
At the time of last reporting, Veness Adam M was the SVP, General Counsel and Sec. of Dianthus Therapeutics, Inc. /de/. (stock ticker symbol DNTH).
Also see all insider trading activities at Dianthus Therapeutics, Inc. /de/.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | DNTH | 0 | $0 | 30,000 | $2,425,800 | 30,000 | $536,400 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | XLRN | 0 | $0 | 10,119 | $1,434,882 | 11,150 | $369,470 |
| 2020 | XLRN | 0 | $0 | 9,309 | $760,524 | 6,000 | $167,820 |
| 2019 | XLRN | 0 | $0 | 4,630 | $206,424 | 0 | $0 |
1. Dianthus Therapeutics, Inc. /de/ (DNTH)
2. Acceleron Pharma Inc (XLRN)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-06-17 | DNTH | Sale | 30,000 | 80.86 | 2,425,800 |
| 2026-06-17 | DNTH | Option Ex | 30,000 | 17.88 | 536,400 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-11-09 | XLRN | Option Ex | 4,500 | 29.37 | 132,165 |
| 2021-09-21 | XLRN | Option Ex | 6,650 | 35.69 | 237,305 |
| 2021-09-21 | XLRN | Sale | 6,650 | 150.05 | 997,832 |
| 2021-09-08 | XLRN | Sale | 6 | 130.00 | 780 |
| 2021-09-09 | XLRN | Sale | 1,407 | 130.00 | 182,910 |
| 2021-01-05 | XLRN | Sale | 2,056 | 123.23 | 253,360 |
| 2020-09-08 | XLRN | Sale | 2,000 | 89.53 | 179,050 |
| 2020-04-08 | XLRN | Option Ex | 6,000 | 27.97 | 167,820 |
| 2020-04-08 | XLRN | Sale | 6,000 | 85.62 | 513,720 |
| 2020-01-02 | XLRN | Sale | 434 | 52.83 | 22,928 |
| 2020-01-03 | XLRN | Sale | 875 | 51.23 | 44,826 |
| 2019-09-10 | XLRN | Sale | 824 | 45.47 | 37,463 |
| 2019-08-09 | XLRN | Sale | 3,268 | 45.00 | 147,060 |
| 2019-07-16 | XLRN | Sale | 538 | 40.71 | 21,901 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Veness Adam M (SVP, General Counsel and Sec. of Dianthus Therapeutics, Inc. /de/ at the time of this reporting) see the Securities and Exchange Commission (SEC) website.